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ABSTRACT
Background Strontium ranelate is currently used for
osteoporosis. The international, double-blind, randomised,
placebo-controlled Strontium ranelate Efficacy in Knee
OsteoarthrItis triAl evaluated its effect on radiological
progression of knee osteoarthritis.
Methods Patients with knee osteoarthritis (Kellgren and
Lawrence grade 2 or 3, and joint space width (JSW)
2.5–5 mm) were randomly allocated to strontium ranelate
1 g/day (n=558), 2 g/day (n=566) or placebo (n=559).
The primary endpoint was radiographical change in JSW
(medial tibiofemoral compartment) over 3 years versus
placebo. Secondary endpoints included radiological
progression, Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) score, and knee pain. The
trial is registered (ISRCTN41323372).
Results The intention-to-treat population included 1371
patients. Treatment with strontium ranelate was
associated with smaller degradations in JSW than
placebo (1 g/day: −0.23 (SD 0.56) mm; 2 g/day: −0.27
(SD 0.63) mm; placebo: −0.37 (SD 0.59) mm);
treatment-placebo differences were 0.14 (SE 0.04), 95%
CI 0.05 to 0.23, p<0.001 for 1 g/day and 0.10 (SE 0.04),
95% CI 0.02 to 0.19, p=0.018 for 2 g/day. Fewer
radiological progressors were observed with strontium
ranelate (p<0.001 and p=0.012 for 1 and 2 g/day).
There were greater reductions in total WOMAC score
(p=0.045), pain subscore (p=0.028), physical function
subscore (p=0.099) and knee pain (p=0.065) with
strontium ranelate 2 g/day. Strontium ranelate was well
tolerated.
Conclusions Treatment with strontium ranelate 1 and
2 g/day is associated with a significant effect on structure
in patients with knee osteoarthritis, and a beneficial effect
on symptoms for strontium ranelate 2 g/day.
INTRODUCTION
Osteoarthritis is characterised by degeneration of car-
tilage and other structures in the joint, including
subchondral bone.1 It is the most prevalent joint
disease, and up to 40% of those over 65 may suffer
from knee or hip osteoarthritis.2 Current manage-
ment strategies focus on relieving symptoms and
improving function through non-pharmacological
and pharmacological approaches, and surgical proce-
dures, including osteotomy, subchondral bone
stimulation and possibly joint distraction, with the
final option of joint replacement if these efforts
fail.1 3 Pharmacological approaches include analge-
sics, anti-inflammatory agents, intra-articular corti-
costeroids or hyaluronic acid, glucosamine sulphate,
chondroitin sulphate or some experimental treat-
ments, none of which are registered as structure-
modifying.
Strontium ranelate is currently indicated for the
management of postmenopausal osteoporosis, and
may be hypothesised to act on both cartilage and
subchondral bone. Preclinical in vitro studies indicate
that it inhibits subchondral bone resorption4 and sti-
mulates cartilage matrix formation in normal and
osteoarthritic human chondrocytes.5 6 Exploratory
analyses suggest that 3 years’ treatment with stron-
tium ranelate attenuates radiological progression of
spinal osteoarthritis and improves back pain.7 The
aim of the 3-year international, double-blind, rando-
mised, placebo-controlled trial—Strontium ranelate
Efficacy in Knee OsteoarthrItis triAl (SEKOIA)—
described herein was to evaluate the effect of stron-
tium ranelate on radiological and clinical progression
of knee osteoarthritis.
METHODS
Study design and patients
SEKOIA was an international, multicentre, rando-
mised, double-blind, placebo-controlled phase 3 trial
in outpatients with knee osteoarthritis mainly in
secondary care. This 3-year study was performed in
98 centres in 18 countries. The selection criteria
defined eligible patients as Caucasian ambulatory
men and women aged ≥50 years with knee
osteoarthritis according to American College of
Rheumatology criteria,8 with pain on at least half of
the days of the previous month (intensity ≥40 mm
on a 100-mm visual analogue scale). On radiography,
included patients were Kellgren and Lawrence9 grade
2 (ie, definite osteophytes and possible narrowing of
joint space) or grade 3 (ie, moderate multiple osteo-
phytes, definite narrowing of joint space and some
sclerosis, and possible deformity of bone ends), and
had joint space width ( JSW) of 2.5 to 5 mm with
predominant knee osteoarthritis of the medial tibio-
femoral compartment. The investigator defined the
target knee at selection. If both knees fulfilled the
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selection criteria, the target knee was the most painful; if both
were equally painful, the target had the highest Kellgren and
Lawrence grade and/or the lowest JSW; and if both had the same
radiological score, the target knee was defined by the investiga-
tor ’s judgement. Exclusion criteria included knee prosthesis,
recent intra-articular injection (notably glucocorticoids
<3 months previously or hyaluronic acid <6 months previously),
clinical deformities, secondary knee osteoarthritis, previous treat-
ments acting on cartilage or bone metabolism (eg, oral or intra-
venous bisphosphonates <1 year previously, teriparatide or
raloxifene <7 days prior to selection, and oral glucosamine
≥1500 mg/day and chondroitin sulphate <3 months previously),
and a medical history or a high risk of venous thromboembolism
(contraindication for strontium ranelate). Further details of other
inclusion and exclusion criteria, and more information on trial
design, have been published elsewhere.10
The study conformed to the principles of the Declaration of
Helsinki; it was approved by the ethics committee or institu-
tional review board of every site. All patients provided written
informed consent before randomisation. The trial is registered
(ISRCTN41323372).
Treatment allocation and masking
At inclusion, patients were randomly allocated to three treatment
groups (strontium ranelate 1 or 2 g/day or placebo) using a centra-
lised interactive voice response system with balanced randomisa-
tion stratified by centre and gender (block size, 3). Patients were
instructed to take one sachet daily of study treatment with water
at bedtime after a 2-h fast. Patients and investigators were blinded
to treatment allocation, and study treatments had identical
appearance. During the study, patients were allowed physiother-
apy, rehabilitation, alternative medicines and pain relief as neces-
sary. Except for study medication, any pain medication was to be
stopped at least five half-lives before a visit for symptom assess-
ment. The investigators instructed their patients how long they
had to stop pain medication prior to a visit, giving a number of
days defined for each available treatment in a specific country.
Treatments acting on cartilage (chondroitin, glucosamine sul-
phate ≥1500 mg) or bone metabolism (bisphosphonates), and
glucocorticoids (oral, inhaled >1500 μg/day, or intra-articular,
except in cases of medical need) were not allowed.10 The first
patient visit was on 28 April 2006 and recruitment ended on 10
March 2008. The last visit was on 17 February 2011.
Interventions and outcomes
Knee radiographs were performed on both knees at selection
and then annually on the target knee alone or upon
withdrawal (patients treated >6 months), using a standardised
technique described elsewhere.10 Briefly, the radiographer
recorded a fixed flexion posterioanterior view (fixed angle 10°),
using a SynaFlexer positioning frame (Synarc Inc, San Francisco,
California, USA).11 Quality control procedures (Synarc Inc,
Hamburg) included specifications related to image acquisition
and collection (eg, depiction, positioning and beam angle);
regular training for radiology technicians; determination of radio-
graphical eligibility; and onsite and centralised digitisation and
quality control of radiographs.10 All radiographs were measured
centrally (INSERM UMR 1033, Lyon, France) by a single reader
blinded to treatment allocation and patient identity. Each
blinded post-baseline image was measured in comparison
with the inclusion image to optimise reproducibility and
sensitivity.12–14
Minimal JSW (mm) at the medial tibiofemoral compartment
was measured using a standardised computer-assisted method,
as described elsewhere.10 15 In short, magnification was deter-
mined (radio-opaque ruler) and a region of interest was delim-
ited by a horizontal tangent to the inferior edges of each
femoral condyle and two perpendiculars to the condylar
margins. Within an area defined automatically by two parallel
lines 15mm apart (with one 10 mm from the condyle line), the
observer delineated the tibial and femoral bone margins, to
depict a polygon; JSW was the diameter of the smallest circle
(automatically calculated) included in this polygon. Intrareader
reproducibility was evaluated at yearly intervals, using 70 knee
radiographs unlinked to the study; it was satisfactory (intra-
class correlation coefficient for JSW >0.90).12 A second reading
was performed by a single reader in another centre (Liege,
Belgium), independently of the first centre, using the same
method; inter-reader reproducibility was good (intraclass correl-
ation coefficient for JSW >0.90).
Other investigations included Western Ontario and McMaster
Universities Osteoarthritis Index (WOMAC) and global knee pain
(visual analogue scale) at inclusion and six monthly intervals.
WOMAC evaluates osteoarthritis health status and outcomes via
24 questions,16 expressed as a total score and pain, stiffness and
physical function subscores. Each subscore is normalised to
100 mm and the total WOMAC score is the sum of the three nor-
malised subscores, that is, maximal value is 300 mm, with the
lower scores indicating a better status. Urine samples were col-
lected at baseline, at 3, 6 and 12 months, and at yearly intervals
thereafter, for assessment of C telopeptide of type II procollagen
(CTX-II), a biomarker for cartilage turn-over (performed by
Supreme SA, Liege, Belgium, using an ELISA, Urine CartiLaps,
ImmunDiagnostic System Nordic, Denmark). Compliance was
evaluated by sachet counts. Safety assessment included recording
of adverse events and clinical and laboratory parameters.
The primary endpoint was radiographical change in JSW from
baseline to last evaluation over 3 years in treatment groups versus
placebo. Secondary endpoints included radiological progression
( joint space narrowing ( JSN) ≥0.5 mm over 3 years); radioclinical
progression ( JSN ≥0.5 mm, and lack of improvement in
WOMAC pain (≤20%) over 3 years); WOMAC scores; global knee
pain; and urinary CTX-II levels.
Statistical methods
At the time of the study design, the literature data on JSN pro-
gression were unclear, and a possible extension of the follow-up
time to 3 years was planned if radiological progression was
lower than expected. The initial sample size calculation esti-
mated that 960 patients would be necessary for >90% power,
assuming an SD of 0.7 and a 40% dropout rate to detect a sig-
nificant between-group difference in JSN of 0.3 mm at 2 years
(two-sided Dunnett test, 5% type I error). This was amended
to 0.2 mm (±10%, ie, between 0.18 and 0.22 mm) in May
2007, following new findings of a lower progression in JSN in
the placebo group than previously published,17 leading to an
estimated sample size of 2127 patients. In March 2008, the
Executive Committee decided to prolong the study to 3 years,
in view of results of a blinded re-estimation of radiological pro-
gression (212 patients) indicating JSN of 0.06±0.42 mm after
1 year. The final estimated sample size was therefore 1600
patients allowing a treatment-placebo difference in JSN of
0.2 mm (±10%) at 3 years with an SD of 0.5 mm.
All efficacy analyses were conducted according to the
intention-to-treat (ITT) principle. The ITT population included
all randomised patients who had taken at least one dose of
treatment and who had an assessable baseline and one post-
baseline evaluation of JSW.
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Baseline characteristics are presented as numbers (%) or mean
±SD. Treatment-placebo difference in primary endpoint from
baseline to last value was analysed using a general linear model
with baseline, centre and gender as covariates, producing esti-
mates and SEs of the adjusted differences, 95% CIs (Dunnett
type) and p values (adjusted according to Dunnett-Hsu18).
A range of sensitivity analyses (described in online supplementary
table S1) were conducted to investigate the impact of missing
data on treatment effect. For secondary outcomes, treatment-
placebo differences in radiological and radioclinical progression
from baseline to last value were analysed as estimates of the
between-group difference (SE) with associated 95% CI and p
value (χ2 test). Treatment-placebo differences in WOMAC scores
and global knee pain were analysed using mixed model for
repeated measurements and the adjusted general linear model.
Treatment effect was studied using a Mann-Whitney-Wilcoxon
test for CTX-II (non-Gaussian distribution). Safety data are pre-
sented as number (%) of events.
The two-sided type I error rate was set at 5%. The results
were analysed by the Biostatistics Division of the Institut de
Recherches Internationales Servier, using SAS (V.9.1). The main
analysis was confirmed by the Department of Public Health
Epidemiology and Health Economics, University of Liege,
Belgium.
Role of the funding source
The Executive Committee was responsible for the study design,
interpretation of the results, and manuscript preparation; they
had full access to study data. The sponsor was responsible for
data management and statistical analyses. The sponsor sup-
ported the work of the Executive Committee, but made no sci-
entific or research decisions independent of this committee.
RESULTS
Three thousand four hundred and thirty-eight patients were
selected, 1683 were included and allocated to treatment (558 stron-
tium ranelate 1 g/day; 566 strontium ranelate 2 g/day; and 559
placebo) and 974 (58%) patients completed the study (figure 1).
The ITT population included 1371 patients (82% of randomised
patients) followed for 29.8±10.5 months (mean±SD).
There were no relevant between-group differences at baseline
(table 1). Mean age of the randomised patients was 62.9
±7.5 years with a majority of women (70%). Body mass index
was 29.9±5.0 kg/m2. The target knee JSW was 3.50±0.84 mm
at baseline, patients were Kellgren and Lawrence grade 2 (62%)
or 3 (38%) and total WOMAC score was 132.4±62.4 mm.
The mean duration of knee osteoarthritis was 76.7
±77.7 months (about 6.4 years). One thousand three hundred
and four (76%) patients reported a medical history of musculo-
skeletal or connective tissue disorders, mainly back pain (9%),
arthralgia (8%), osteopenia (5%) and osteoporosis (5%). At
inclusion, 1148 (68%) patients were taking treatment for
osteoarthritis, mainly propionic acid-related treatments (18%),
acetic acid derivatives (12%) or anilides (32%). Only seven
patients were taking glucosamine and one chondroitin sul-
phate. In general, 39% of the patients were receiving analgesics,
and three patients systemic corticosteroids for their osteoarth-
ritis. There were no relevant differences in baseline characteris-
tics between completed and withdrawn patients, between
randomised and ITT populations or between ITT groups at
baseline (table 1).
Mean compliance was 93.3±9.3% (ITT population). During
the study, 1278 patients (76% of the randomised set) received
at least one concomitant treatment for osteoarthritis, mainly
propionic acid derivatives (25%), acetic acid derivatives (18%)
and anilides (39%). Forty-six per cent of the patients took
analgesics with an indication for osteoarthritis, 13 patients
received glucosamine, three chondroitin sulphate, and two a
combination of the two agents; 5% of the patients received sys-
temic corticoids for their osteoarthritis. There was no relevant
between-group difference (see online supplementary table S2).
JSN in the placebo group was −0.37±0.59 mm over the
study. Treatment with strontium ranelate was associated with
significantly attenuated JSN versus placebo, with −0.23
±0.56 mm for 1 g/day and −0.27±0.63 mm for 2 g/day from
baseline to end (table 2). The estimate of the treatment-placebo
difference was significant for both dosages (p<0.001 for 1 g/day
Figure 1 Trial profile. ITT, intention to treat (population). *Patients could have more than one reason.
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and p=0.018 for 2 g/day) (figure 2). Similar results were found
in the second reading and a range of sensitivity analyses to
assess the impact of missing data (see online supplementary
table S1).
There were significantly fewer radiological and radioclinical
progressors with strontium ranelate 1 and 2 g/day (table 2).
Treatment with strontium ranelate 2 g/day was associated with
significantly lower WOMAC total score (p=0.045) and pain
Table 1 Demographical and clinical characteristics at baseline in randomised patients and in the ITT population
Randomised patients (N=1683) ITT population (N=1371)
Strontium ranelate
1 g/day (n=558)
Strontium ranelate
2 g/day (n=566) Placebo (n=559)
Strontium ranelate
1 g/day* (n=445)
Strontium ranelate
2 g/day* (n=454) Placebo (n=472)*
Demographical parameters
Age (years) 62.4 (7.4) 63.5 (7.5) 62.8 (7.5) 62.3 (7.0) 63.1 (7.3) 62.8 (7.3)
Sex (female) 394 (71%) 399 (71%) 392 (70%) 309 (69%) 311 (69%) 326 (69%)
Body mass index (kg/m2) 30.1 (5.1) 29.8 (4.8) 29.8 (5.1) 30.1 (5.1) 29.7 (4.8) 29.6 (5.1)
Disease characteristics (target knee)
Joint space width (mm) 3.45 (0.87) 3.54 (0.80) 3.51 (0.83) 3.45 (0.86) 3.53 (0.80) 3.51 (0.82)
Duration of knee osteoarthritis (months) 78.8 (78.1) 76.6 (78.9) 74.8 (76.3) 80.0 (77.9) 75.6 (76.6) 76.6 (76.8)
Kellgren and Lawrence scale
Grade 1 2 (<1%) 1 (<1%) – 2 (<1%) 1 (<1%) –
Grade 2 341 (61%) 347 (61%) 350 (63%) 268 (60%) 274 (60%) 299 (63%)
Grade 3 214 (38%) 218 (39%) 209 (37%) 174 (40%) 179 (40%) 173 (37%)
Physical assessment
Swelling 92 (17%) 91 (16%) 104 (19%) 69 (16%) 70 (16%) 88 (19%)
Warmth 26 (5%) 17 (3%) 22 (4%) 20 (5%) 12 (3%) 14 (3%)
Effusion 70 (13%) 60 (11%) 72 (13%) 52 (12%) 46 (10%) 66 (14%)
Pain (VAS) (mm/100 mm) 52.6 (22.5) 55.6 (21.9) 53.7 (22.4) 51.6 (22.4) 55.7 (22.1) 53.7 (22.5)
WOMAC scale†
Total score 132.0 (62.0) 136.4 (62.5) 129.0 (62.5) 130.2 (60.9) 136.1 (62.6) 128.3 (62.0)
Pain subscore 42.7 (21.3) 44.5 (21.8) 42.2 (21.6) 42.1 (21.0) 44.7 (22.1) 41.8 (21.5)
Stiffness subscore 46.8 (24.9) 48.3 (25.0) 45.5 (25.2) 46.0 (24.7) 48.3 (24.6) 45.2 (25.0)
Physical function subscore 42.5 (21.9) 43.7 (22.5) 41.0 (22.4) 41.8 (21.4) 43.5 (22.7) 40.9 (22.3)
Data are number of patients (%) or means (SD).
*No significant difference for any variable between the corresponding groups for randomised or ITT patients.
†WOMAC score is measured on a 300-mm scale; WOMAC subscores are normalised to 100 mm.
ITT, intention-to-treat; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
Table 2 Outcomes in the intention-to-treat population (n=1371)
Strontium ranelate 1 g/day (n=445) Strontium ranelate 2 g/day (n=454) Placebo (n=472)
Value
Difference versus
placebo
E (SE), (95% CI) p Value Value
Difference versus
placebo
E (SE), (95% CI) p Value Value
Primary endpoint, mean (SD)
Joint space width (mm) −0.23 (0.56) 0.14 (0.04)
(0.05 to 0.23)
<0.001 −0.27 (0.63) 0.10 (0.04)
(0.02 to 0.19)
0.018 −0.37 (0.59)
Progression of disease, n(%)
Radiological progression* 99 (22%) −10.80 (2.9)
(−16.54 to −5.06)
<0.001 116 (26%) −7.50 (3.0)
(−13.34 to −1.66)
0.012 156 (33%)
Radioclinical progression† 32 (8%) −3.94 (1.98)
(−7.83 to −0.05)
0.049 28 (7%) −5.12 (1.91)
(−8.86 to −1.37)
0.008 53 (12%)
Symptoms of disease, mean (SD)‡
WOMAC total score (/300 mm) −41.8 (62.3) −1.3 (4.0)
(−9.0 to 6.5)
0.749 −51.9 (66.1) −8.0 (4.0)
(−15.7 to −0.2)
0.045 −40.7 (69.1)
WOMAC pain subscore (/100 mm) −14.6 (22.6) 0.1 (1.3)
(−2.6 to 2.7)
0.969 −19.1 (23.7) −3.0 (1.3)
(−5.6 to −0.3)
0.028 −14.7 (23.5)
WOMAC stiffness subscore (/100 mm) −15.6 (26.9) −1.0 (1.6)
(−4.1 to 2.1)
0.523 −18.3 (28.0) −2.5 (1.6)
(−5.6 to 0.6)
0.120 −14.0 (29.4)
WOMAC physical function subscore (/100 mm) −12.2 (21.1) −0.4 (1.3)
(−3.0 to 2.2)
0.772 −15.0 (22.2) −2.2 (1.3)
(−4.7 to 0.4)
0.099 −11.7 (23.2)
Global knee pain (VAS), (/100 mm) −22.9 (29.0) −0.24 (1.64)
(−3.45 to 2.97)
0.884 −28.5 (28.3) −3.01 (1.60)
(−6.20 to 0.19)
0.065 −24.2 (29.2)
Values are number (%) at end for progressors, mean (SD) change from baseline to end for symptoms.
*Joint space narrowing ( JSN) ≥0.5 mm over 3 years.
†JSN ≥0.5 mm and lack of improvement in WOMAC pain (≤20%) pain over 3 years.
‡WOMAC score is evaluated on a 300-mm scale; WOMAC subscores are normalised to 100 mm, and global knee pain is reported on a 100-mm scale.
VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index.
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subscore (p=0.028), and a trend toward lower physical
function subscore (p=0.099) and global knee pain (p=0.065)
(table 2, figure 2). None of these reductions was significant at
1 g/day. Urinary CTX-II decreased in all groups, and the
between-group difference in the relative change was significant
for both dosages versus placebo (p=0.003 for 1 g/day and
p=0.021 for 2 g/day).
The change in JSW from baseline was significantly different
from placebo in both treatment groups at 12, 24 and
36 months, with no difference between the dosages at any
time (p=0.601 at 12 months, p=0.149 at 24 months and
p=0.311 at 36 months). The reduction in total WOMAC score
and pain subscore was numerically greater with treatment than
placebo at every visit, with a significant between-group differ-
ence for pain subscore at 36 months (p=0.029 for 2 g/day).
The treatment-placebo difference in radiological and radioclini-
cal progressors was significant in both treatment groups at
every visit (figure 3).
Strontium ranelate was well tolerated (table 3).19 The rate of
venous thromboembolic events was <1% in all groups, and
there were no cases of drug reaction with eosinophilia and sys-
temic symptoms. There were no relevant differences in clinical
or laboratory parameters, with the possible exception of creat-
ine phosphokinase, which increased from baseline with treat-
ment (11.7±85.6 and 20.7±104.4 IU/l with 1 and 2 g/day,
respectively), but not placebo (−0.4±68.1 IU/l); eight patients
(three, one and four patients in the 1 g/day, 2 g/day, and
placebo groups, respectively) had values greater than five times
the upper limit of normal.
DISCUSSION
Our results demonstrate that strontium ranelate has structure-
modifying activity in patients with knee osteoarthritis, with
significantly smaller degradations in JSW over the study
(p<0.001 for 1 g/day and p=0.018 for 2 g/day vs placebo).
There were fewer patients with radiographical and radioclinical
progression of osteoarthritis in the treatment groups.
Additionally to this structural effect, symptomatic improve-
ment was observed, with a significant impact on WOMAC
total score and pain subscore (p=0.045 and p=0.028, respect-
ively), and a trend towards improvement in global knee pain
(p=0.065) at 2 g/day, but not 1 g/day. The safety profile of
strontium ranelate was satisfactory, in line with knowledge of
this agent.20 21 There was a slight mean increase in creatine
phosphokinase in the treated groups as previously described for
strontium ranelate.20 Pooled analysis in osteoporotic patients
treated with strontium ranelate showed that increases were
mainly mild, transient and reversible22; they were not asso-
ciated with any clinical muscular symptoms.
These results come from a single study with a large sample
size. The robustness of our observation of a structure-
modifying effect for strontium ranelate is demonstrated by a
range of sensitivity analyses and the rigorous methodology
used for radiography acquisition and reading.10 In this context,
the trial was carried out in accordance with current European
and US regulatory guidelines,23 24 in terms of design and effi-
cacy evaluation.
Osteoarthritis is not a uniform disease entity, and different
phenotypes clearly exist, driven by variable changes in bone,
cartilage and synovium; the links between these phenotypes
are unclear.1 Strontium ranelate may exert structure-modifying
effects through influences on chondrocyte and bone cell func-
tion. Evidence to support an action on cartilage via chondro-
cytes includes: the treatment-placebo difference in urinary
CTX-II in our study, which suggests lower cartilage metabolism
and possibly reduced osteophyte formation; a report that stron-
tium ranelate stimulates cartilage matrix formation in vitro,5
implying restoration of the balance between chondrocyte for-
mation and resorption; a direct effect of strontium ranelate on
proteoglycan synthesis5; and an indirect effect on insulin
growth factor-1 (IGF-1).6 25
Strontium ranelate is known to influence bone; however, it is
unclear whether its effect on cartilage is direct or secondary to
an effect on subchondral bone. Defective subchondral bone
metabolism in osteoarthritis could modify chondrocytes in car-
tilage via local factors released during subchondral bone remod-
elling.26 Strontium ranelate may decrease in vitro subchondral
bone resorption via the osteoprotegerin/RANK ligand pathway
Figure 2 Effect of strontium ranelate on outcomes in knee
osteoarthritis from baseline to end. (A) Change in joint space width
(mm). (B) Change in total Western Ontario and McMaster Universities
Osteoarthritis Index (WOMAC) score. (C) Change in WOMAC pain
subscore. p Values are presented versus placebo.
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in subchondral osteoblasts and by downregulating metallopro-
teases 2 and 9.4 Similar findings have been reported for stron-
tium ranelate in osteoporotic bone.27 28 These effects on
subchondral bone may directly alter the progression of osteo-
arthritis, or modify cartilage response to mechanical loading.
We observed differential effects of the two doses of strontium
ranelate: structure appeared to be modified at both 1 and 2 g/day,
while symptoms required 2 g/day for significant amelioration.
This supports published evidence for different aetiological
pathways in structural and symptomatic osteoarthritis.29
Osteoarthritic pain may have several causes (synovitis, osteo-
phytes and bone marrow oedema), which are all related to inflam-
mation or bone, rather than cartilage, which is considered to be
aneural. We could hypothesise that both dosages affect the aetio-
logical pathways leading to structure modification, but only 2 g/
day has an additional effect on pain, possibly through its action
on bone though further clinical and preclinical studies are required
to explore this in more depth. In line with this, strontium ranelate
has strong dose-dependent effects on bone mineral density in
osteoporosis with a clinical effect at 2 g/day.30 Further evidence to
support heterogeneity between structure and symptoms is the
inconsistency noted between radiological grade and knee pain or
function.31 32 Alternative interpretations include floor and ceiling
effects in pain outcome measures; and the fluctuating symptom-
atic natural history of osteoarthritis.33 These results raise the
interesting question of whether structure modification and pain
relief can both be gained by a single drug or whether a combin-
ation of drugs would be necessary in osteoarthritis.
Strontium ranelate 2 g/day would therefore be the most
appropriate dosage for clinical practice since it was associated
with a 27% reduction in radiological JSN (a surrogate of cartilage
loss) versus placebo. This translates into nearly a year of average
radiological osteoarthritis progression saved over 3 years.
Moreover, our results imply that 14 patients (95% CI 9 to 57)
would need to be treated with 2 g/day strontium ranelate over
the study duration to prevent one case of radiological progres-
sion ≥0.5 mm, a threshold known to predict osteoarthritis-
related surgery.34 Moreover, the modification of structure
observed in patients with knee osteoarthritis with strontium
ranelate in our study is clinically relevant, since it is accompan-
ied by a beneficial effect on symptoms.
There are several limitations to our study. One is the difficulty
of evaluating the magnitude of pain changes due to both a rela-
tively high placebo response, which is common to all other osteo-
arthritis trials,35 and the difficult interpretation of changes
evaluated as means as opposed to individual improvements. The
dropout rate (14% annualised; mostly for non-medical reasons
(consent withdrawal)) could be regarded as a limitation; however,
the annualised rate is similar to those reported for other osteo-
arthritis trials (11% to 16%).17 33 36–40 Aside from a possible role
Figure 3 Impact of strontium ranelate on disease progression:
percentage of patients who were radiological progressors (JSN ≥0.5 mm
vs baseline, top) and radioclinical progressors (JSN ≥0.5 mm and lack of
improvement in WOMAC pain (≤20%) vs baseline, bottom) at 12, 24,
and 36 months. p Values are presented versus placebo.
Table 3 Emergent adverse events according to the summary of product characteristics19 and those leading to drug withdrawal
Patients with an event (%) Patients with an event leading to treatment withdrawal (%)
Strontium ranelate
1 g/day (n=548)
Strontium ranelate
2 g/day (n=564) Placebo (n=556)
Strontium ranelate
1 g/day (n=548)
Strontium ranelate
2 g/day (n=564) Placebo (n=556)
Gastrointestinal disorders
Diarrhoea 32 (6%) 44 (8%) 24 (4%) 6 (1%) 9 (2%) 8 (1%)
Nausea 19 (4%) 21 (4%) 21 (4%) 5 (0.9%) 7 (1%) 3 (0.5%)
Vomiting 11 (2%) 9 (2%) 7 (1%) 1 (0.2%) 2 (0.4%) 3 (0.5%)
Venous thromboembolism events
Deep venous thrombosis 4 (0.7%) 1 (0.2%) 1 (0.2%) 2 (0.4%) 1 (0.2%) –
Pulmonary embolism 2 (0.4%) 2 (0.4%) 1 (0.2%) 1 (0.2%) 1 (0.2%) 1 (0.2%)
Skin and subcutaneous disorders
Dermatitis 1 (0.2%) 5 (0.9%) 1 (0.2%) – 1 (0.2%) –
Allergic dermatitis 8 (2%) 6 (1%) 3 (0.5%) 2 (0.4%) 4 (0.7%) 2 (0.4%)
Eczema 5 (0.9%) 11 (2%) 6 (1%) – 1 (0.2%) 1 (0.2%)
Rash 4 (0.7%) 4 (0.7%) 10 (2%) 1 (0.2%) 1 (0.2%) 2 (0.4%)
Data are number of events or number of patients (%) in patients included in the study who had taken at least one dose of study drug.
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of the disease itself, the rate of withdrawals may be affected by
study duration and the number of assessments in a relatively
young population. This was anticipated in the sample size calcu-
lations, and sensitivity analyses demonstrated minimal impact of
missing data. Moreover, the baseline characteristics of dropouts
were similar to those of the ITT population and completers,
implying that premature withdrawal did not lead to the selection
of a particular subpopulation. Another limitation is the possibil-
ity of different phenotypes in osteoarthritis,1 suggesting that
strontium ranelate might be more effective in certain subgroups
of osteoarthritis patients, for example, those with dominant sub-
chondral bone changes. Finally, like all studies of this type, poten-
tial causes of radiographical JSN other than cartilage thinning,
such as meniscal extrusion, cannot be excluded.
In conclusion, treatment with strontium ranelate 1 and 2 g/day
was associated with a significant effect on structure in patients
with knee osteoarthritis. Additionally to this structure-modifying
activity, there was a beneficial effect on symptoms at 2 g/day.
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